The upregulation of GSDMB in HER2-positive gastric cancer cells provides a theoretical basis for the efficacy of IBI315, suggesting the potential application of GSDMB in gastric cancer immunotherapy (Lin et al., 2023). Here, ERBB2 is linked to gastric cancer.